For example, NVP-BKM120 (buparlisib), an oral pan-class I PI3K inhibitor belonging to the 2,6-dimorpholino pyrimidine derivative family, was shown to inhibit T-ALL proliferation while dephosphorylating AKT and S6RP in vitro. Here, PIK3CB is linked to acute lymphoblastic leukemia.